Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 4/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23126466 | 1.00 | RET (0.33) | RETGFERKCNH2KDM4ELMNA | |
| SCHEMBL23064048 | 0.91 | KCNH2 (0.31) | KCNH2 | |
| SCHEMBL30809734 | 0.90 | RET (0.33) | RET | |
| SCHEMBL23063925 | 0.80 | — | — | |
| SCHEMBL30809737 | 0.79 | RET (0.34) | RET | |
| SCHEMBL23126467 | 0.78 | RET (0.38) | RET | |
| SCHEMBL30809735 | 0.78 | RET (0.38) | RET | |
| SCHEMBL30809736 | 0.78 | RET (0.38) | RET | |
| SCHEMBL23064010 | 0.78 | RET (0.31) | RET | |
| SCHEMBL30677163 | 0.78 | RET (0.31) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932643-B2 | Substituted heterocyclic inhibitors of PTPN11 | NAVIRE PHARMA, INC. (US) | 2024-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932643-B2 | Substituted heterocyclic inhibitors of PTPN11 | PTPN11, PTPRJ, PTPRCAP | RET 121/4885GFER 3560/4885KCNH2 4200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.